title: Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.
abstract: BACKGROUND
  The recommended standard of care calls for treating opioid-dependent pregnant women with methadone and observing neonates exposed in utero for five to seven postnatal days to see if treatment for neonatal abstinence syndrome (NAS) is needed. Data from a large multi-site randomized clinical trial comparing buprenorphine vs. methadone for the treatment of opioid dependence during pregnancy suggest buprenorphine-exposed neonates had less severe NAS, but may require pharmacologic treatment for NAS later than methadone-exposed neonates. The present study examined whether time to pharmacologic treatment initiation differed in a relatively large non-blinded clinical sample of buprenorphine- vs. methadone-exposed neonates treated for NAS.
  
  
  METHODS
  Medical records for 75 neonates exposed to buprenorphine (n=47) or methadone (n=28) in utero who required treatment for NAS were examined. Time elapsed between birth and initiation of pharmacologic treatment was calculated for each neonate and time to treatment initiation compared between groups.
  
  
  RESULTS
  Median time to treatment initiation (hours:minutes, IQR) was significantly later in buprenorphine- vs. methadone-exposed neonates (71:02, 44:21-96:27 vs. 34:12, 21:00-55:41, respectively, p<.001). Estimates of mean time to treatment initiation from parametric analyses that adjusted for maternal and neonatal characteristics were very similar (73:10 (95% CI: 61:00-87:18) vs. 42:36 (95% CI: 33:06-53:30), respectively, p=.0005). This difference was not dependent on maternal age or neonatal sex, gestational age, or birth weight.
  
  
  CONCLUSIONS
  These findings confirm results from randomized clinical trials, adding generality to the observation that buprenorphine-exposed neonates require treatment significantly later than methadone-exposed neonates.
authors.affiliation: University of Vermont, Department of Psychiatry, 1 South Prospect Street UHC, Burlington, VT 05401, USA; University of Vermont, Department of Psychology, 1 South Prospect Street UHC, Burlington, VT 05401, USA. Electronic address: dgaalema@uvm.edu.
authors.forename: Diann E
authors.initials: DE
authors.lastname: Gaalema
authors.forename: Sarah H
authors.initials: SH
authors.lastname: Heil
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Badger
authors.forename: Jerilyn S
authors.initials: JS
authors.lastname: Metayer
authors.forename: Anne M
authors.initials: AM
authors.lastname: Johnston
mesh_terms: D001724:Birth Weight; D002047:Buprenorphine / Q000009:adverse effects*; D016022:Case-Control Studies; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008691:Methadone / Q000009:adverse effects*; D009357:Neonatal Abstinence Syndrome / Q000188:drug therapy*; D058850:Opiate Substitution Treatment / Q000379:methods*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D002047:Buprenorphine; D008691:Methadone
keywords: Buprenorphine; Methadone; NAS; Neonatal abstinence syndrome; Opioids; Pregnancy; Treatment; neonatal abstinence syndrome